MedPath

FDA Warns Against BioZorb Markers Due to Adverse Events

• The FDA advises against using BioZorb and BioZorb LP Markers due to reported adverse events following Hologic's voluntary recall. • Hologic recalled all lots of unused BioZorb Markers after receiving complaints of pain, infection, and device migration in breast tissue. • The FDA recommends healthcare providers quarantine and return unused markers and monitor patients with implanted devices for adverse events. • Patients experiencing adverse effects from BioZorb Markers should contact their healthcare provider, but device removal is not always necessary.

The FDA has issued a safety communication advising against the use of BioZorb Markers and BioZorb LP Markers, implantable radiographic biomarkers used in soft tissues, including breast tissue. This alert follows Hologic's voluntary recall on October 25, 2024, of all lots of unused BioZorb Markers due to reports of serious adverse events (AEs) in patients with implanted devices.
Hologic's initial alert to healthcare providers on February 27, 2024, highlighted potential health risks associated with BioZorb Markers. As of October 16, 2024, the company had received 399 complaints out of 91,531 devices sold since 2015, with 188 linked to AEs. These complaints included pain, infection, rash, device migration, device erosion, seroma, discomfort, and other complications related to the device's presence in the breast, sometimes requiring device removal.
BioZorb Markers consist of a plastic component designed to dissolve over a year or more and a permanent titanium component. They are indicated for radiographic marking of sites in soft tissue for future treatment. The FDA emphasizes that these markers are not intended to improve cosmetic outcomes, fill space, or serve as markers for radiation therapy.

FDA Recommendations

The FDA has issued specific recommendations for patients and healthcare providers.
For Patients and Caregivers:
  • Contact your healthcare provider if you experience any adverse effects with the device.
  • Device removal is not necessary unless advised by a healthcare provider.
  • Discuss potential risks with healthcare providers if radiation therapy is planned, as the FDA has not cleared or approved BioZorb Markers for this use.
  • Report any problems or complications with the device to the FDA.
For Healthcare Providers and Facilities:
  • Do not implant BioZorb Markers.
  • Quarantine and return all unused BioZorb Markers to Hologic.
  • Review and discuss patient recommendations with those who have received a BioZorb Marker implant.
  • Be aware of serious AEs following BioZorb Marker placement in breast tissue.
  • Continue monitoring patients with implanted BioZorb Markers for signs of AEs.
  • Be aware that the FDA has not cleared or approved the devices to fill space in the tissue, improve cosmetic outcomes, or as a marker for radiation treatment.
  • Report any problems or complications experienced after BioZorb Marker placement to the FDA.
The FDA will continue collaborating with Hologic to monitor reports of issues with BioZorb Markers and will keep the public informed of any significant new information. Individuals are encouraged to report any problems experienced with the devices via the MedWatch Voluntary Reporting Form.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Issues Black Box Warning for Fezolinetant (Veozah) Due to Liver Injury Risk

The FDA issued a black box warning for fezolinetant (Veozah) due to rare but serious liver injury risks associated with the drug.
The warning advises regular liver blood testing for women taking Veozah to monitor and mitigate potential liver damage.

FDA Investigates Blood Cancer Risk Linked to Bluebird Bio's Skysona Gene Therapy

The FDA is investigating Bluebird Bio's Skysona gene therapy due to reports of hematologic malignancies, including myelodysplastic syndrome and acute myeloid leukemia.
These adverse events were observed in clinical trials, with diagnoses occurring 14 to 92 months post-treatment, raising concerns about long-term safety.

Applied Therapeutics Awaits FDA Decision on Govorestat for Galactosemia

Applied Therapeutics is seeking FDA approval for govorestat, a novel aldose reductase inhibitor, for the treatment of galactosemia, a rare metabolic disorder.
Govorestat aims to reduce the production of galactitol, a toxic metabolite that causes neurological damage in galactosemia patients, with no currently approved therapies.

FDA Approves Zolbetuximab for CLDN18.2-Positive Gastric and GEJ Adenocarcinoma

The FDA approved zolbetuximab (Vylov) in combination with chemotherapy for first-line treatment of CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma.
The approval was based on the SPOTLIGHT and GLOW trials, which demonstrated improved progression-free survival with zolbetuximab plus chemotherapy.

FDA Warns Against BioZorb Markers Following Recall Due to Adverse Events

The FDA has issued a warning against the use of BioZorb and BioZorb LP Markers due to reports of adverse events, subsequent to a voluntary recall by Hologic.
Patients with BioZorb implants have reported complications such as pain, infection, device migration, and rash, sometimes necessitating further treatment or device removal.

XYRA Receives FDA Guidance on Budiodarone Labeling for Atrial Fibrillation Management with Wearable Monitoring

XYRA has secured FDA guidance for incorporating wearable atrial fibrillation (AF) monitoring devices into the drug label for budiodarone, a potential treatment for non-permanent AF.
The FDA's guidance specifies directions for use to control AF symptoms and reduce stroke risk by eliminating long episodes of AF (LEAF) exceeding 5 hours, as demonstrated in Phase 2 trials.

FDA Decisions Loom for Biofrontera, BMS, and Zealand Pharma

Biofrontera seeks FDA approval for a higher dose of Ameluz to treat actinic keratosis, potentially improving convenience for patients with large affected areas.
Bristol Myers Squibb awaits a decision on Opdivo for perioperative treatment of resectable non-small cell lung cancer, based on Phase III data showing improved event-free survival.

FDA Nears Decisions on Key Therapies for Gastroparesis, Niemann-Pick Disease, Schizophrenia, COPD, Mesothelioma, and Post-Surgical Pain

The FDA is expected to decide on Vanda Pharmaceuticals' tradipitant for gastroparesis by September 18, potentially offering a novel NK-1R antagonist treatment option.
Zevra Therapeutics awaits a verdict by September 21 on arimoclomol for Niemann-Pick disease type C, an ultrarare neurodegenerative disorder with no approved therapies.

FDA Updates Veozah Label with Warning for Rare but Serious Liver Injury

The FDA has issued a warning for Veozah (fezolinetant) regarding rare but serious liver injury in patients using the drug for hot flashes due to menopause.
The updated label includes recommendations for increased frequency of liver blood testing during treatment, specifically monthly for the first two months.

FDA Adds Guillain-Barré Syndrome Warning to RSV Vaccines Abrysvo and Arexvy

The FDA has mandated a warning for Guillain-Barré Syndrome (GBS) be included in the prescribing information for the RSV vaccines Abrysvo and Arexvy.
This decision follows post-marketing surveillance indicating a potential increased risk of GBS, a rare autoimmune disorder, in individuals receiving these vaccines.

Reference News

[1]
FDA Advises Against Use of BioZorb Markers in Breast Cancer and Other Indications
onclive.com · Oct 30, 2024

The FDA advises against using BioZorb Markers and BioZorb LP Markers due to serious adverse effects, prompting Hologic's...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy